Research Analysts Set Expectations for Medtronic Q1 Earnings

Medtronic plc (NYSE:MDT) – Analysts at William Blair lowered their Q1 2026 earnings per share (EPS) estimates for shares of Medtronic in a note issued to investors on Wednesday, May 21st. William Blair analyst M. Andrew now expects that the medical technology company will post earnings of $1.23 per share for the quarter, down from their prior estimate of $1.33. The consensus estimate for Medtronic’s current full-year earnings is $5.46 per share. William Blair also issued estimates for Medtronic’s Q2 2026 earnings at $1.33 EPS, Q3 2026 earnings at $1.37 EPS, Q4 2026 earnings at $1.60 EPS, FY2026 earnings at $5.54 EPS, Q1 2027 earnings at $1.33 EPS, Q2 2027 earnings at $1.39 EPS, Q4 2027 earnings at $1.76 EPS and FY2027 earnings at $5.94 EPS.

Several other research analysts have also recently issued reports on MDT. Wall Street Zen cut Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday. Royal Bank of Canada dropped their price objective on shares of Medtronic from $105.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday. Mizuho cut their target price on shares of Medtronic from $100.00 to $98.00 and set an “outperform” rating for the company in a research report on Thursday. Citigroup upgraded shares of Medtronic from a “neutral” rating to a “buy” rating and increased their price target for the stock from $92.00 to $107.00 in a research report on Tuesday, March 4th. Finally, UBS Group boosted their price objective on shares of Medtronic from $85.00 to $95.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Medtronic presently has a consensus rating of “Hold” and an average price target of $96.07.

Medtronic Stock Performance

Shares of MDT opened at $80.70 on Friday. The firm has a market capitalization of $103.51 billion, a P/E ratio of 24.53, a PEG ratio of 2.22 and a beta of 0.81. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.90 and a quick ratio of 1.39. Medtronic has a one year low of $75.96 and a one year high of $96.25. The business has a fifty day moving average of $85.06 and a 200 day moving average of $86.44.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Wednesday, May 21st. The medical technology company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.04. Medtronic had a net margin of 12.83% and a return on equity of 14.07%. The firm had revenue of $8.93 billion during the quarter, compared to analysts’ expectations of $8.81 billion. During the same period in the previous year, the company earned $1.46 earnings per share. The firm’s quarterly revenue was up 3.9% on a year-over-year basis.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Olstein Capital Management L.P. boosted its stake in Medtronic by 8.0% during the fourth quarter. Olstein Capital Management L.P. now owns 94,000 shares of the medical technology company’s stock valued at $7,509,000 after buying an additional 7,000 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of Medtronic by 2.7% during the 4th quarter. Empowered Funds LLC now owns 105,822 shares of the medical technology company’s stock worth $8,453,000 after acquiring an additional 2,778 shares in the last quarter. Caprock Group LLC raised its holdings in shares of Medtronic by 12.6% during the 4th quarter. Caprock Group LLC now owns 47,767 shares of the medical technology company’s stock worth $3,849,000 after acquiring an additional 5,363 shares in the last quarter. Synergy Asset Management LLC boosted its position in shares of Medtronic by 107.1% during the 4th quarter. Synergy Asset Management LLC now owns 227,802 shares of the medical technology company’s stock valued at $19,353,000 after acquiring an additional 117,809 shares during the last quarter. Finally, Equitable Trust Co. grew its holdings in shares of Medtronic by 91.7% in the fourth quarter. Equitable Trust Co. now owns 39,645 shares of the medical technology company’s stock valued at $3,167,000 after purchasing an additional 18,968 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 11th. Shareholders of record on Friday, June 27th will be paid a $0.71 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $2.84 annualized dividend and a yield of 3.52%. This is a boost from Medtronic’s previous quarterly dividend of $0.70. Medtronic’s payout ratio is presently 85.11%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.